The DOI matches its Crossref record; 159 of the 159 references it cites were found in a registry or an index.
Nanodrug Delivery: Is the Enhanced Permeability and Retention Effect Sufficient for Curing Cancer?
Open accessAbstract
Nanotechnology offers several attractive design features that have prompted its exploration for cancer diagnosis and treatment. Nanosized drugs have a large loading capacity, the ability to protect the payload from degradation, a large surface on which to conjugate targeting ligands, and controlled or sustained release. Nanosized drugs also leak preferentially into tumor tissue through permeable tumor vessels and are then retained in the tumor bed due to reduced lymphatic drainage. This process is known as the enhanced permeability and retention (EPR) effect. However, while the EPR effect is widely held to improve delivery of nanodrugs to tumors, it in fact offers less than a 2-fold increase in nanodrug delivery compared with critical normal organs, resulting in drug concentrations that are not sufficient for curing most cancers. In this Review, we first overview various barriers for nanosized drug delivery with an emphasis on the capillary wall's resistance, the main obstacle to delivering drugs. Then, we discuss current regulatory issues facing nanomedicine. Finally, we discuss how to make the delivery of nanosized drugs to tumors more effective by building on the EPR effect.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Angiogenesis in cancer and other diseases
Carmeliet, P., & Jain, R. K. (2000) · Nature · doi:10.1038/35025220 · Cited by 9,070
Matsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,781
Heart Disease and Stroke Statistics—2016 Update: A Report From the American Heart Association
Mozaffarian, D., Benjamin, E. J., Go, A. S., Arnett, D. K., Blaha, M. J., Cushman, M., Das, S. R., de Ferranti, S., Després, J.-P., Fullerton, H. J., et al. (2016) · Circulation · doi:10.1161/cir.0000000000000350 · Cited by 6,596
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527
The extracellular matrix at a glance
Frantz, C., Stewart, K. M., & Weaver, V. M. (2010) · Journal of Cell Science · doi:10.1242/jcs.023820 · Cited by 4,334
Fang, J., Nakamura, H., & Maeda, H. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.04.009 · Cited by 3,559
Delivering nanomedicine to solid tumors
Jain, R. K., & Stylianopoulos, T. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.139 · Cited by 3,180
The extracellular matrix: A dynamic niche in cancer progression
Lu, P., Weaver, V. M., & Werb, Z. (2012) · Journal of Cell Biology · doi:10.1083/jcb.201102147 · Cited by 3,024
Pericytes: Developmental, Physiological, and Pathological Perspectives, Problems, and Promises
Armulik, A., Genové, G., & Betsholtz, C. (2011) · Developmental Cell · doi:10.1016/j.devcel.2011.07.001 · Cited by 2,653
Molecular regulation of vessel maturation
Jain, R. K. (2003) · Nature Medicine · doi:10.1038/nm0603-685 · Cited by 2,529
Cited by
Cisplatin: The first metal based anticancer drug
Ghosh, S. (2019) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2019.102925 · Cited by 1,751
The entry of nanoparticles into solid tumours
Sindhwani, S., Syed, A. M., Ngai, J., Kingston, B. R., Maiorino, L., Rothschild, J., MacMillan, P., Zhang, Y., Rajesh, N. U., Hoang, T., et al. (2020) · Nature Materials · doi:10.1038/s41563-019-0566-2 · Cited by 1,732
Monro, S., Colón, K. L., Yin, H., Roque, J., Konda, P., Gujar, S., Thummel, R. P., Lilge, L., Cameron, C. G., & McFarland, S. A. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00211 · Cited by 1,461
Polymeric Nanoparticles for Drug Delivery
Beach, M. A., Nayanathara, U., Gao, Y., Zhang, C., Xiong, Y., Wang, Y., & Such, G. K. (2024) · Chemical Reviews · doi:10.1021/acs.chemrev.3c00705 · Cited by 1,155
Rethinking cancer nanotheranostics
Chen, H., Zhang, W., Zhu, G., Xie, J., & Chen, X. (2017) · Nature Reviews Materials · doi:10.1038/natrevmats.2017.24 · Cited by 1,102
Therapeutic Nanoparticles and Their Targeted Delivery Applications
Yetisgin, A. A., Cetinel, S., Zuvin, M., Kosar, A., & Kutlu, O. (2020) · Molecules · doi:10.3390/molecules25092193 · Cited by 1,080
Smart nanocarrier-based drug delivery systems for cancer therapy and toxicity studies: A review
Hossen, S., Hossain, M. K., Basher, M. K., Mia, M. N. H., Rahman, M. T., & Uddin, M. J. (2019) · Journal of Advanced Research · doi:10.1016/j.jare.2018.06.005 · Cited by 998
“Both the phenomena are collectively known as the EPR effect [171].”
BackgroundMesoporous Silica Nanoparticles for Drug Delivery
Manzano, M., & Vallet‐Regí, M. (2020) · Advanced Functional Materials · doi:10.1002/adfm.201902634 · Cited by 939
Kalyane, D., Raval, N., Maheshwari, R., Tambe, V., Kalia, K., & Tekade, R. K. (2019) · Materials Science and Engineering: C · doi:10.1016/j.msec.2019.01.066 · Cited by 849
The Uniqueness of Albumin as a Carrier in Nanodrug Delivery
Spada, A., Emami, J., Tuszynski, J. A., & Lavasanifar, A. (2021) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.1c00046 · Cited by 591
Survey of Clinical Translation of Cancer Nanomedicines—Lessons Learned from Successes and Failures
He, H., Liu, L., Morin, E. E., Liu, M., & Schwendeman, A. (2019) · Accounts of Chemical Research · doi:10.1021/acs.accounts.9b00228 · Cited by 588
Molecularly Imprinted Polymers: Antibody Mimics for Bioimaging and Therapy
Haupt, K., Medina Rangel, P. X., & Bui, B. T. S. (2020) · Chemical Reviews · doi:10.1021/acs.chemrev.0c00428 · Cited by 561
Overcoming barriers in photodynamic therapy harnessing nano-formulation strategies
Xie, J., Wang, Y., Choi, W., Jangili, P., Ge, Y., Xu, Y., Kang, J., Liu, L., Zhang, B., Xie, Z., et al. (2021) · Chemical Society Reviews · doi:10.1039/d0cs01370f · Cited by 522
Engineering mesoporous silica nanoparticles for drug delivery: where are we after two decades?
Vallet-Regí, M., Schüth, F., Lozano, D., Colilla, M., & Manzano, M. (2022) · Chemical Society Reviews · doi:10.1039/d1cs00659b · Cited by 507
Peptide and protein nanoparticle conjugates: versatile platforms for biomedical applications
Spicer, C. D., Jumeaux, C., Gupta, B., & Stevens, M. M. (2018) · Chemical Society Reviews · doi:10.1039/c7cs00877e · Cited by 497
Hersh, A. M., Alomari, S., & Tyler, B. M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084153 · Cited by 478
The tumor EPR effect for cancer drug delivery: Current status, limitations, and alternatives
Sun, R., Xiang, J., Zhou, Q., Piao, Y., Tang, J., Shao, S., Zhou, Z., Bae, Y. H., & Shen, Y. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114614 · Cited by 433
RNAi-based therapeutics and tumor targeted delivery in cancer
Kara, G., Calin, G. A., & Ozpolat, B. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114113 · Cited by 411
Advances in nanomaterial-based targeted drug delivery systems
Cheng, X., Xie, Q., & Sun, Y. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1177151 · Cited by 395
Bridging Bio–Nano Science and Cancer Nanomedicine
Björnmalm, M., Thurecht, K. J., Michael, M., Scott, A. M., & Caruso, F. (2017) · ACS Nano · doi:10.1021/acsnano.7b04855 · Cited by 382
Kwon, S., Ko, H., You, D. G., Kataoka, K., & Park, J. H. (2019) · Accounts of Chemical Research · doi:10.1021/acs.accounts.9b00136 · Cited by 370
Nanomaterials for Nanotheranostics: Tuning Their Properties According to Disease Needs
Wong, X. Y., Sena-Torralba, A., Álvarez-Diduk, R., Muthoosamy, K., & Merkoçi, A. (2020) · ACS Nano · doi:10.1021/acsnano.9b08133 · Cited by 363
The Chemistry of Reticular Framework Nanoparticles: MOF, ZIF, and COF Materials
Ploetz, E., Engelke, H., Lächelt, U., & Wuttke, S. (2020) · Advanced Functional Materials · doi:10.1002/adfm.201909062 · Cited by 350
Functionalizing nanoparticles with cancer-targeting antibodies: A comparison of strategies
Marques, A. C., Costa, P. J., Velho, S., & Amaral, M. H. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.01.035 · Cited by 349
Targeting Topoisomerase I in the Era of Precision Medicine
Thomas, A., & Pommier, Y. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1089 · Cited by 337
Strategies to improve the EPR effect: A mechanistic perspective and clinical translation
Ikeda-Imafuku, M., Wang, L. L.-W., Rodrigues, D., Shaha, S., Zhao, Z., & Mitragotri, S. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.03.043 · Cited by 330
Biocompatible Semiconductor Quantum Dots as Cancer Imaging Agents
McHugh, K. J., Jing, L., Behrens, A. M., Jayawardena, S., Tang, W., Gao, M., Langer, R., & Jaklenec, A. (2018) · Advanced Materials · doi:10.1002/adma.201706356 · Cited by 318
New keys for old locks: carborane-containing drugs as platforms for mechanism-based therapies
Stockmann, P., Gozzi, M., Kuhnert, R., Sárosi, M. B., & Hey-Hawkins, E. (2019) · Chemical Society Reviews · doi:10.1039/c9cs00197b · Cited by 317
Nanoparticles' interactions with vasculature in diseases
Tee, J. K., Yip, L. X., Tan, E. S., Santitewagun, S., Prasath, A., Ke, P. C., Ho, H. K., & Leong, D. T. (2019) · Chemical Society Reviews · doi:10.1039/c9cs00309f · Cited by 314
The Emerging Role of Multifunctional Theranostic Materials in Cancer Nanomedicine
Figueiredo, P., Bauleth-Ramos, T., Hirvonen, J., Sarmento, B., & Santos, H. A. (2018) · Handbook of Nanomaterials for Cancer Theranostics · doi:10.1016/b978-0-12-813339-2.00001-3 · Cited by 287
Smart Design of Nanomaterials for Mitochondria‐Targeted Nanotherapeutics
Liew, S. S., Qin, X., Zhou, J., Li, L., Huang, W., & Yao, S. Q. (2021) · Angewandte Chemie International Edition · doi:10.1002/anie.201915826 · Cited by 286
Magnesium sensing via LFA-1 regulates CD8+ T cell effector function
Lötscher, J., Martí i Líndez, A.-A., Kirchhammer, N., Cribioli, E., Giordano Attianese, G. M. P., Trefny, M. P., Lenz, M., Rothschild, S. I., Strati, P., Künzli, M., et al. (2022) · Cell · doi:10.1016/j.cell.2021.12.039 · Cited by 277
Pande, S. (2023) · Artificial Cells, Nanomedicine, and Biotechnology · doi:10.1080/21691401.2023.2247036 · Cited by 258
The mechanisms of nanoparticle delivery to solid tumours
Nguyen, L. N. M., Ngo, W., Lin, Z. P., Sindhwani, S., MacMillan, P., Mladjenovic, S. M., & Chan, W. C. W. (2024) · Nature Reviews Bioengineering · doi:10.1038/s44222-024-00154-9 · Cited by 257
Cancer stem cells-emanated therapy resistance: Implications for liposomal drug delivery systems
Dianat-Moghadam, H., Heidarifard, M., Jahanban-Esfahlan, R., Panahi, Y., Hamishehkar, H., Pouremamali, F., Rahbarghazi, R., & Nouri, M. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.08.043 · Cited by 140
Ho, Y. T., Kamm, R. D., & Kah, J. C. Y. (2018) · Nanoscale · doi:10.1039/c8nr02393j · Cited by 102
The enigmatic world of fungal melanin: A comprehensive review
Suthar, M., Dufossé, L., & Singh, S. K. (2023) · Journal of Fungi · doi:10.3390/jof9090891 · Cited by 95
“Additionally, melanin NPs are strongly biocompatible, easier to eject from common organs like the liver and kidneys, and have fewer harmful effects when they accumulate over time in organs [140].”
BackgroundWang, Y., Ma, J., Qiu, T., Tang, M., Zhang, X., & Dong, W. (2021) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2021.105864 · Cited by 71
Banerjee, S. R., Foss, C. A., Horhota, A., Pullambhatla, M., McDonnell, K., Zale, S., & Pomper, M. G. (2017) · Biomacromolecules · doi:10.1021/acs.biomac.6b01485 · Cited by 54
Hoogenboezem, E. N., Patel, S. S., Lo, J. H., Cavnar, A. B., Babb, L. M., Francini, N., Gbur, E. F., Patil, P., Colazo, J. M., Michell, D. L., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-45609-0 · Cited by 52
Beygi, M., Oroojalian, F., Hosseini, S. S., Mokhtarzadeh, A., Kesharwani, P., & Sahebkar, A. (2023) · Progress in Materials Science · doi:10.1016/j.pmatsci.2023.101209 · Cited by 32
RetractedSakamoto, K., Qi, Y., & Miyako, E. (2023) · Scientific Reports · doi:10.1038/s41598-023-27825-8 · Cited by 14
Hybrid Multifunctional Nanomaterials for Diagnostic and Therapeutic Applications
Lagopati, N., Efstathopoulos, E. P., Veroutis, D., Katifelis, H., Theocharous, G., Pantelis, P., Evangelou, K., Gorgoulis, V. G., & Gazouli, M. (2022) · Nanotechnology in the Life Sciences · doi:10.1007/978-3-031-12658-1_17 · Cited by 6
Metadata
- Authors
- Nakamura, Y., Mochida, A., Choyke, P. L., & Kobayashi, H.
- Venue
- Bioconjugate Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2016-09-02
- Volume
- 27
- Issue
- 10
- Pages
- 2225-2238
- ISSN
- 1043-1802 (ISSN-L)
- 1520-4812
- OpenAlex
- W2518509288
- Cited by
- 1,101
- References
- 159
- FWCI
- 29.82
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.